Literature DB >> 26759348

Nivolumab-induced organizing pneumonia in a melanoma patient.

Tasuku Sano1, Hisashi Uhara2, Yasutomo Mikoshiba1, Aya Kobayashi1, Ryuhei Uchiyama1, Kazunari Tateishi3, Hiroshi Yamamoto3, Ryuhei Okuyama1.   

Abstract

We report the case of a 70-year-old woman with vaginal melanoma and multiple metastases in the lung. After the third dose of nivolumab, decreased room-air resting arterial oxygen saturation with bilateral basal fine crackles on auscultation developed despite the absence of respiratory symptoms. Computed tomography showed ground-glass opacities with airspace consolidations scattered with a peculiar distribution, and most were observed around the existing metastatic tumors in the lung. From the 42nd day to the 56th day after the last administration of nivolumab, she received dexamethasone 1-2 mg/body for the prevention of adverse events after stereotactic radiation for brain metastasis. At 3 months after the last administration of nivolumab, a computed tomography scan revealed improvement of the pneumonia and a decreased size and number of metastatic lesions in the lung, although some lesions showed enlargement. Further examination is needed to clarify the relationship between the pattern of pneumonia after Nivo therapy and clinical effects.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  PD-1; drug induced lung disease; melanoma; nivolumab

Mesh:

Substances:

Year:  2016        PMID: 26759348     DOI: 10.1093/jjco/hyv199

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  14 in total

Review 1.  Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.

Authors:  Tyler Lazaro; Priscilla K Brastianos
Journal:  CNS Oncol       Date:  2017-04

Review 2.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

3.  Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).

Authors:  Tsukasa Ishiwata; Takahiro Ebata; Shunichiro Iwasawa; Jun Matsushima; Satoshi Ota; Yukio Nakatani; Kenji Tsushima; Yuji Tada; Koichiro Tatsumi; Yuichi Takiguchi
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

4.  Pembrolizumab-induced pneumonitis.

Authors:  Vincent Leroy; Carole Templier; Jean-Baptiste Faivre; Arnaud Scherpereel; Clement Fournier; Laurent Mortier; Lidwine Wemeau-Stervinou
Journal:  ERJ Open Res       Date:  2017-05-02

5.  Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.

Authors:  Toru Kumagai; Madoka Kimura; Takako Inoue; Motohiro Tamiya; Kazumi Nishino; Fumio Imamura
Journal:  Thorac Cancer       Date:  2017-03-30       Impact factor: 3.500

Review 6.  Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Ricardo Costa; Benedito A Carneiro; Mark Agulnik; Alfred W Rademaker; Sachin G Pai; Victoria M Villaflor; Massimo Cristofanilli; Jeffrey A Sosman; Francis J Giles
Journal:  Oncotarget       Date:  2017-01-31

7.  Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.

Authors:  Eun Young Kim; Inkeun Park; Young Saing Kim; Hee Kyung Ahn; Hee Young Lee; Jeong Ho Kim
Journal:  Thorac Cancer       Date:  2019-02-07       Impact factor: 3.500

8.  Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?

Authors:  Sameep Sehgal; Vamsidhar Velcheti; Sanjay Mukhopadhyay; James K Stoller
Journal:  Respir Med Case Rep       Date:  2016-09-08

9.  Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab.

Authors:  Ryoji Kato; Hidetoshi Hayashi; Junko Tanizaki; Kaoru Tanaka; Masayuki Takeda; Kazuhiko Nakagawa
Journal:  ESMO Open       Date:  2017-03-28

10.  Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series.

Authors:  Padmastuti Akella; Sundaravadivel Loganathan; Vishal Jindal; Jamal Akhtar; Amos Lal
Journal:  Respir Med Case Rep       Date:  2018-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.